Pharmaceutical

J&J trims neuroscience pipeline – seltorexant in Alzheimer’s disease dropped 

J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.

Oct 18, 2024 - 04:00
J&J trims neuroscience pipeline – seltorexant in Alzheimer’s disease dropped 
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.
Read the original article

Tags:

Previous Article

Lexicon partners Viatris for global expansion of sotagliflozin

Next Article

Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to gover...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

After early-stage breast cancer, interrupting endocrine therapy to become pregnant didn’t raise risk of recurrence

After early-stage breast cancer, interrupting endocrine...

May 3, 2023

ASCO 2023: Summit Therapeutics plans to rise with bispecific NSCLC data

ASCO 2023: Summit Therapeutics plans to rise with bispe...

Jun 5, 2023

Opinion: The misguided reason why providers aren’t prescribing more buprenorphine for opioid use disorder

Opinion: The misguided reason why providers aren’t pres...

Jan 6, 2024